AU665526B2 - Method of directing biosynthesis of specific polyketides - Google Patents

Description

-7

I?

OPI DATE 03/08/93 AOJP DATE 14/10/93 APPLN. ID 12450/92 II lllll 11 1111 lllll PCT NUMBER PCT/US92/004 7 I 11111111111111111111111111111111111111 AU9212450 INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (51) International Patent Classification 5 (11) International Publication Number: WO 93/13663 A01N 43/22, A61K 31/71 A, C37H 17/08, C12N 1/21 International Publication Date: 22 July 1993 (22.07.93) C12P 19/62 (21) International Application Number: PCT/US92/00427 (81) Designated States: AU, CA, JP, KR, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, MC, NL, (22) International Filing Date: 17 January 1992 (17.01.92) SE).

(71) Applicant: ABBOTT LABORATORIES [US/US]; CHAD Published D-377/AP6D-2, One Abbott Park Road, Abbott Park, IL With intcrnational search report.

60064-3500 (US).

(72) Inventors: KATZ, Leonard 844 NortL Avenue, Waukegan, IL 60085 DONADIO, Stefano 110 Brookhill Road, Libertyville, IL 60048 MCALPINE, James, 6 P. 211 West Rockland Road, Libertyville, IL 60048

(US).

(74) Agents: GORMAN, Edward, Hoover, Jr. et al.; Abbott Laboratories, CHAD D-377/AP6D-2, One Abbott Park Road, Abbott Park, IL 60064-3500 (US).

(54)Title: METHOD OF DIRECTING BIOSYNTHESIS OF SPECIFIC POLYKETIDES (57) Abstract A method to produce novel polyketide structures by designing and introducing specified changes in the DNA governing the synthesis of the polyketide is disclosed. The biosynthesis of specific polyketide analogs is accomplished by genetic manipulation of a polyketide-producing microorganism by isolating a polyketide biosynthetic gene-containing DNA sequence, identifying enzymatic activities associated within the DNA sequence, introducing one or more specified changes into the DNA sequence which codes for one of the enzymatic activities which results in an altered DNA sequence, introducing the altered DNA sequence into the polyketide-producing microorganism to replace the original sequence, growing a culture of the altered microorganism under conditions suitable for the formation of the specific polyketide analog, and isolating the specific polyketide analog from the culture. The method is most useful when the segment of the chromosome modified is involved in an enzymatic activity associated with polyketide biosynthesis, particularly for manipulating polyketide synthase genes from Saccharapolyspora or Streptomyces.

WO 93/13663 PCT/US92/00427 METHOD OF DIRECTING BIOSYNTHESIS OF SPECIFIC POLYKETIDES Field of the Invention.

The present invention relates to a method for directing the biosynthesis of specific polyketide analogs by genetic manipulation. In particuar, polyketide biosynthetic genes are manipulated to produce precise, novel polyketides of predicted structure.

1 0 Background of the Invention Polyketides are a large class of natural products that includes many important antibiotics and immunosuppressants such as erythromycins, tetracyclines, and rapamycins. Their synthesis proceeds by an ordered condensation of acyl esters to generate carbon chains of varying length and 1 5 substitution pattern that are later converted to mature polyketides. This process has long been recognized as resembling fatty acid biosynthesis, but with important differences. Unlike a fatty acid synthase, a typical polyketide synthase is programmed to make many choices during carbon chain assembly: For example, the choice of "starter" and "extender" units, which are often selected from acetate, propionate or butyrate residues in a defined sequence. The choice of using a full cycle of reductiondehydration-reduction after some condensation steps, omitting it completely, or using one of two incomplete cycles (reduction alone or reduction followed by dehydration), which determines the pattern of keto or hydroxyl groups and the degree of saturation at different points in the chain is additionally programed. Finally the choice of stereochemistry for the substituents at many of the carbon atoms is programmed by the polyketide synthase.

Because of the commercial significance of Streptomyces, a great 3 0 amount of effort has been expended in the study of Streptomyces genetics.

Consequently much is known about Streptomyces and several cloning vectors exist for transformations of the organism.

Although many polyketides have been identified, there remains the need to obtain novel polyketide structures with enhanced properties.

3 5 Current methods of obtaining such molecules include screening of natural isolates and chemical modification of existing polyketides, both of which are costly and time consuming. Current screening methods-are based on gross properties of the molecule, i.e. antibacterial, antifungal L J 2 activity, etc., and both a priori knowledge of the structure of the molecules obtained or predetermination of enhanced properties are virtually impossible. Chemical modification of preexisting structures has been successfully employed, but it still suffers from practical limitations to the type of compounds obtainable, largely connected to the poor yield of multistep syntheses and available chemistry to effect modifications. The following modifications are extremely difficult or inefficient at the present time: change of the stereochemistry of the side chains in the completed polyketide; change of the length of the i polyketide by removal or addition of carbon units from the interior of the acyl chain; and dehydroxylation at unique positions in the acyl chain. Accordingly, there exists the need to obtain molecules wherein such changes can be specified and performed and would represent an improvement in the technology to produce altered polyketide molecules with predicated structure.

Summary of the Invention A method for directing the biosynthesis of specific polyketide analogs by genetic manipulation of a polyketide-producing microorganism, wherein said biosynthesis proceeds enzymatically by repeated condensation of carbonyl-containing extender units to an acyl starter unit or to a growing polyketide, each condensation adding two additional carbons to a backbone polyketide chain to synthesize a polyketide of defined length having a P-carbonyl group, said method comprising the steps of: isolating a polyketide biosynthetic gene-containing DNA sequence from a polyketide-producing microorganism of interest; identifying within said gene-containing DNA sequence the DNA fragment or Sfragments encoding for an enzymatic activity that is to be altered to produce said specific polyketide analog; introducing one or more specified changes into said gene containing DNA S* sequence, thereby resulting in an altered DNA sequence which, when translated, results in altered enzymatic activity to produce said specific polyketide analog; introducing said altered DNA sequence into a polyketide producing microorganism to replace the original sequence; growing a culture of the altered microorganism under conditions suitable for the formation of the specific polyketide analog; and isolating said specific polyketide analog from the culture.

The present method is most useful when the segment of the chromosome modified is involved in an enzymatic activity associated with polyketide biosynthesis. The present invention is especially useful IN:\LIBFF00261 :SAK WO 93/13663 PCT/US92/00427 3 in manipulating polyketide biosynthetic genes from Streptomyces, an organism which provides over one-half of the clinically useful antibiotics.

Brief Description of the Drawings FIG. 1 illustrates the organization of gene encoding polyketide synthase and designated eryA as follows: Map coordinates of the DNA; DOTPLOT of the output of COMPARE (window 50, stringency 32) program (Sequence Analysis Software Package of the Genetics Computer Group, University of Wisconsin, Biotechnology Center, 1710 University 1 0 Avenue, Madison, Wisconsin 53705 of eryA segment (x-axis) vs.

subsegment of eryA comprises between 23 27.5 sequence coordinates (yaxis) [see Fig. Open reading frame organization of eryA and enzymatic activities encoded. PT propionyltransferase; ACP acyl carrier protein; KS=P-ketoacyl ACP synthase; RmT (2R) methylmalonyl 1 5 CoA transferase; KR =P-ketoreductase; SmT (2S) methylmalonyl CoA transferase; DH dehydratase; ER enoylreductase; TE thioesterase; and Schematic diagram showing the extent of each of the six modules in eryA.

FIG. 2. illustrates the nucleotide sequence of eryA with corresponding translation of the three open reading frames. Standard one letter codes for the amino acids appear beneath their respective nucleic acid codons. The standard one letter codes for the amino acid sequences are as follows: A -alanine R -arginine N -asparagine D -aspartic acid C -cysteine Q -glutamine E -glutamic acid G -glycine H -histidine I -isoleucine 3 5 L -leucine K -lysine M -methionine (start) F -phenylalanine __i WO 93/13663 PCT/US92/00427 4 P -proline S -serine T -threonine W -tryptophan Y -tyrosine V -valine FIG. 3. is a schematic representation of Type I, Type II and Type III changes in eryA and structures of corresponding novel polyketides 1 0 produced. A69 (Type I) and A33 (Type II) represent in-frame deletions of the base pairs in the DNA segments corresponding to the KR of module 2 and the 3-ketoacyl ACP synthase of module 2, respectively. Insertion of a complete copy of module 4 within module 1 is also shown. Production of 11-epifluoro-15-norerythromycin in strain that carries A33 occurs when substrate analog (2S,3S,4S,5S)2,4-dimethyl-3-fluoro-5-hydroxyhexanoic acid-ethyl thioester is fed.

FIG. 4 illustrates the restriction site coordinates of cosmid pR1 5' to the sequence of eryA (Fig 2).

Detailed Description of the Invention For the purposes of the present invention as disclosed and claimed herein, the following terms are defined.

The term "polyketide" as used refers to a large and diverse class of 2 5 natural products, including antibiotics, pigments, and immunosuppressants. Antibiotics include, but are not limited to O anthracyclines, tetracyclines, polyethers, ansamycins, macrolides of different types (polyenes ar avermectins as well as classical macrolides such as erythromycins).

The term "polyketide-producing microorganism" as used herein includes any Actinomycetales which can producec a polyketide. Examples of Actinomycet hat produce polyketides include but are not limited to Micromonospora rosaria, Micromonospora megalomicea, Sacharapolyspora erythraea, Streptomyces antibioticus, Streptomyces albireticuli, Streptomyces ambofasciens, Streptomyces avermitilis, Streptomyces fradiae, Streptomyces hygroscopicus, Streptomyces tsukubaenais, Streptomyces griseus, Streptomyces mycarofasciens, Streptomyces platensis, Streptomyces venezuelae, Streptomyces WO 93/13663 PC/US92/00427 violaceoniger, and various Actinomadurr Dactylosporangium and Nocardia strains that produce polyether type of polyketides.

The term "polyketide synthase" as used herein refers to the complex of enzymatic activities responsible for the biosynthesis of polyketides which include but are not limited to -ketoreductase, dehydratase, acyl carrier protein, enoylreductase, P-ketoacyl ACP synthase, and acyltransferase.

The term "extender" as used herein refers to a coenzyme A thioester of a dicarboxylate which is incorporated into a polyketide by a 1 0 polyketide synthase.

The term "starter" as used herein refers to a coenzyme A thioester of a carboxylic acid which is used by the polyketide synthase as the first building block of the polyketide.

The term "eryA" as used herein refers to the genes involved in the 1 5 formation of the polyketide moiety of erythromycin.

The term "condensation" as used herein refers to the addition of an extender unit out to the nascent polyketide chain and requires the action of P-ketoacyl ACP synthase, acyltransferase, and acyl carrier protein.

The term "P-carbonyl processing" as used herein refers to changes effecting the carbonyl group of the growing polyketide via P-ketoreductase, dehydratase, and enoylreductase.

The term "module" as used hereii refers to the genetic element encoding one condensation step, as defined above, and one P-carbonyl processing step, as defined herein.

The term "Type I change" as used herein refers to changes in DNA sequence which will result in the production of polyketide rings of length identical to that of 6-deoxyerythronolide A, but with altered functional groups at specific ring positions.

The term "Type II change" as used herein refers to alterations which will result in the production of macrolide rings only when fed exogenously with substrate analogs, e.g.thioesitrs of appropriate acyl compounds of various length. Thus Type II mutants are erythromycin non-producing (Ery') mutants. The structure of the resulting macrolides will depend on the substrate employed.

The term 'Type IfI change" as used herein refers to alterations which will result in the biosynthesis of macrolide rings of length reduced (deletion) or increased (insertion) by two carbon units, or macrolide rings altered in specific portions of the chain (replacement).

WO 93/13663 PCT/US92/00427 6 In its broadest sense, the present invention entails a general procedure for producing novel polyketide structures in vivo by selectively altering the genetic information of the organism that naturally produces a related polyketide. A set of examples described herein are a series of novel polyketides that make use of the genetic information for the biosynthesis of the polyketide portion of the macrolide antibiotic erythromycin. The organization of the segment of the Saccharapolyspora erythraea chromosome, designated eryA, and the corresponding polypeptides which it encodes that determine the biosynthesis of the 1 0 polyketide segment of erythromycin, are shown in FIG. 1. It is seen that eryA is organized in modules, as shown, and that each module takes care of one condensation step, through the action of the f-ketoacyl ACP synthase specified within, wherein an extender unit, methylmalonyl CoA, is added first to the starter unit, propionyl CoA, and then to the 1 5 successively growing acyl chain. The precise succession of elongation steps is dictated by the genetic order of the six modules: module 1 determines the first condensation; module 2, the second; module 3, the third, and so on until the sixth condensation step has occurred.

Furthermore, the processing of the growing chain after each condensation is also determined by the information within each module. Thus- 3 ketoreduction of the P-carbonyl takes place after each step except for step 3, as determined by the presence of a functional p-ketoreductase in all modules except module 3, whereas dehydration and enoylreduction only take place after the fourth extender unit is added to the growing acyl chain, as determined by the presence of dehydratase and enoylreductase in module 4. Furthermore, the choice of the correct enantiomer (2R or 2S) of methylmalonyl-CoA as the extender unit employed at each condensation is specified by the acyltransferase function determined by each module (FIG. 1C).

In the present invention, novel polyketide molecules of desired structure are produced by the introduction of specific genetic alterations of the eryA sequence into the Sac, erythraea chromosome. The complete nucleotide sequence of the eryA segment of the Sac. erythraea chromosome and the sequence of the corresponding polypeptides are 3 5 shown in PIG. 2. Three types of alterations to the eryA DNA sequence are described: those nactivating a single function in a module which does not arrest acyl chain growth (0ketoreductase, dehydratase, or enoylreductase); those inactivating a single function in a module i: C7~' WO 93/13663 PCT/US92/00427 7 which does arrest chain growth (-ketoacyl ACP synthase, acyltransferase or acyl carrier protein); and (iii) those affecting an entire module (deletion, insertion, or replacement). The novel polyketides produced by strains carrying these types of mutations can be classified accordingly. Type I changes will result in the production of polyketide rings of length identical to that of 6-deoxyerythronolide A, but with altered fvnctional groups at specific ring positions. Strains carrying type II alterations will result in the production of macrolide rings only when fed exogenously with substrate analogs, e.g.thioesters of appropriate acyl compounds of 1 0 various length. Thus Type II mutants are erythromycin non-producing (Ery') mutants. The structure of the resulting macrolides will depend on the substrate employed. Type III changes will result in the biosynthesis of macrolide rings of length reduced (deletion) or increased (insertion) by two carbon units, or macrolide rings altered in specific portions of the J 1 5 chain (replacement). A schematic representation of some examples of Type I, Type II and Type III alterations in eryA and the corresponding novel polyketides produced in hosts that carry such alterations is shown in FIG. 3.

In the examples described herein, specific mutations in the eryA region of the Sac. erythraea chromosome are introduced by a simple twostep approach: 1) introduction of a specified change in a cloned DNA segment; 2) exchange of the wild type allele with the mutated one. Step 1 requires standard recombinant DNA manipulations employing E. coli as the host. Step 2 requires one or more plasmids out of the several E. coli- 2 5 Sac. erythraea shuttle vectors available and a simple screening procedure for the presence of the colony carrying the altered gene. Two methods are used to introduce the altered allele into the chromosome to replace the wild type allele. The first employs gene replacement, described in Examples 7, 11, 15, 19 and 24, wherein the gene to be altered, a'ong with adjacent upstream and downstream DNA, is mutated and cloned into a Sac. erythraea non-replicating vector. The plasmid carrying the altered allele is then introduced into the host strain by transformation of protoplasts employing selection for a plasmid marker. Since the plasmid does not replicate, regenerated cells that carry the marker have undergone a single homologous recombination between one of the two segments flanking the mutation on the plasmid and its homologous counterpart in the chromosome. Some of the colonies that have subsequently lost the marker will have undergone a secor-l recombination between the other j

I-

lr~b~ WO 93/13663 PCT/US92/00427 8 plasmid borne adjacent DNA segment and its homologous chromosomal counterpart resulting in the retention of the mutation in the chromosome, replacing the normal allele with the mutant one. The second method to introduce an altered allele into the chromosome employs gene conversion, described in Examples 37 and 43. In this method, an Ery" Sac. erythraea strain carrying a deletion of a specified region of the eryA segment of the chromosome is used as a host. Into a Sac. erythraea multicopy plasmid that carries a selectable marker is cloned the wild type counterpart (segment 1) of the eryA segment mutant in the 1 0 host. Subsequently, the desired homologous or heterologous DNA segment to be introduced (segment 2) is cloned within the portion of segment 1 which is deleted in the mutant strain. The resulting plasmid is then introduced into the host employing selection for the marker.

Among the transformants will be a population that have integrated 1 5 segments 1 and 2 from the plasmid by the process of gene conversion which can be verified by examination of the DNA among the colonies that have recovered the ability to produce erythromycin.

Two examples each of Types I, II and l alterations to the eryA DNA sequence and the resultant novel polyketides produced are described in the examples described herein. Examples 1 through 8, 9 through 12 and 13 through 16 describe the construction and effect of three Type I mutants.

Examples 17 through 22 and 23 through 27 describe the construction of two Type II mutants and the effects of feeding two different synthetic substrates to the mutant strains. Examples 28 through 38 and 39 through 44 outline the steps in constructing Type HI changes and their respective effects on the structure of the novel polyketides produced. In Examples I through 7 a plasmid that contains a substantial deletion of the segment of the gene corresponding to the b-ketoreductase of module 5 is created, the altered gene is inserted into the Sac. erythraea chromosome to replace the wild type allele and the new strain carrying the altered gene is identified and isolated. In Example 8, the new strain is fermented and the novel polyketide 5-oxo-5,6-dideoxy-3c-mycarosyl erythronolide B that results from the introduction of the mutant allele is isolated. In Examples 9 through 11, a mutation is introduced into the P-ketoreductase of module 2 and the mutated allele is then used to replace the wild type allele in the chromosome. In Example 12, the strain carrying the altered allele is fermented and the novel compound 11-oxo-11-deoxyerythromycin A is isolated. Similarly, in Examples 13 through 16 a mutation is introduced 9 into the dehydratase of module 4 and the mutated allele is then used to replace the wild type allele in the chromosome. The strain carrying this altered allele is then fermented and the novel products 7-hydroxyerythromycin A and 6-deoxy-7-hydroxyerythromycin A are isolated. In Examples 17 through 21, a mutation is made in the DNA corresponding to the P-ketoacyl-ACP synthase of module 1 and introduced into the chromosome to replace the wild type allele. This mutation has the effect of arresting the synthesis of the polyketide chain and results in the Ery- phenotype. The synthetic substrate (2S,3R,4S,5S)3,5-dihydroxy-2,4-dimethylhexanoic acid-ethyl ester is then made and fed to the mutant resulting in the production of the novel compound (14S,15S)14(1-hydroxyeihyl)erythromycin. Similarly, in Examples 22 through 24, a mutation is created in the P-ketoacyl-ACP synthase of module 2 and introduced into the chromosome to replace the wild type allele. In Example 25 and 26, the synthetic substrate (2S,3S,4S,5S)2,4-dimethyl-3-fluoro-5-hydroxyh xanoic acid-ethyl thioester is made and fed to the module 2 P-ketoacyl-ACP synthase mutant and the resulting novel compound 1l-epifluoro-15-norerythromycin is isolated. In Examples 27 through 38, a copy of the DNA sequence corresponding to module 4 is introduced into the deleted segment of the P-ketoacyl-ACP synthase of module 1 resulting in the production of the novel compound 14(1-propyl)erythromycin. In Examples 40 through 44, a copy of the DNA sequence corresponding to module 5 is introduced into the deleted segment of the P -ketoacyl-ACP synthase of module 1 resulting in the production of the novel compound 14[1(1-hydroxypropyl)]erythromycin.

General Methods Materials, Plasmids and Bacterial Strains Restriction endonucle ses, T4 DNA ligase, nick-translation kit, competent E. coli DH5a cells, X-gal, IPTG, and plasmids pUC19 and pUC12 are purchased from Bethesda Research Laboratories (BRL), Gaithersburg, MD. [a- 32 p]dCTP and Hybond N are from SAmersham Corp., Chicago, IL. Seakem LE agarose and Seaplaque low gelling S, temperature agarose are from FMC Bioproducts, Rockiand, ME. E. coli-Sac shuttle plasmids pWHM3 or pWHM4, resident in E.coli K12 strain, were constructed as described by Vara et al. Bacteriol., 171:5872 (1989)). Similarly, cosmid pSI was constructed as described by Tuan et al. (Gene, 90:21 (1990)). Staphylococcus aureus ThR (thiostrepton resistant) is obtained by plating 108 cells of S. aureus on agar medium containing 10 mg/ml thiostrepton and picking a survivor after 48 hr growth at 37 0

C.

Thiostrepton is obtained from Squibb-Bristol Myers, New Brunswick, NJ. All other chemical and reagents are from standard commercial sources unless specified otherwise.

DNA Manipulations Standard conditions (Maniatis et al., Molecular Cloning, A Laboratory Manual, ,~\^Cold Spring Harbor Laboratory, Cold Spring Harbor, 1982) are employed for -'34 J IN:\LIBFF100261:SAK i 0. 1 3, IWCA 244349 i*lbU'j\0817:GSA egistered Patent Attorney INSTR CODE: 5000 1 of 6 iirestriction endonuclease digestion, agarose gel-electrophoresis, nick translation of DNA to make 32 P-labeled probes, DNA ligation, and transformation of E. coli employing selection for ampicillin resistance (ApR) on LB agar plates. Plasmid DNA is isolated from minipreps of E. coli transformants by the boiling method Maniatis et al., 1982, supra). DNA fragments are recovered from low melting agarose gels using the method of Langridge et al., 1980. Total DNA from Sac. erythraea strains is prepared according to described procedures (Hopwood et al., Genetic Manipulation of Streptomyces, A Laboratory Manual, John Innes Foundation, Norwich, U.K. 1985). DNA is transferred from agarose gels onto Hybond N following the manufacturer's instructions.

Hybridizations are performed in sealed bags containing 10-20 ml of [IxNET (20xNET 3 M NaC1, 0.3 M TrisHC1, 20 mM Na 2 EDTA, pH 5XDenhardt's solution (Maniatis et al., 1982, supra), 0.2 mg/ml denatured calf thymus DNA, 0.2% SDS, and 0.5-2x10 7 cpm of the nick-translated probe] for 16-20 hr at 65 0 C. Filters are washed three times in lxNET/0.1% SDS for 20 min each at room temperature, and once in 0.05xNET/0.1% SDS for 20 min at 70 0 C. Filters are reused as described (Donadio et al., 1990).

Amplification of DNA fragments Synthetic deoxyoligonuleotides are synthesized on an ABI Model 380A synthesizer (Applied Biosystems, Foster City, CA) following the manufacturer's recommendations.

Amplifications of DNA fragments is performed by the polymerase chain reaction (PCR) employing a Coy i t

SI

cSCC

I,

C t :i

C'

IN:\LIBFF100261SAK WO 93/13663 PCT/US92/00427 11 thermocycler. Reactions contain 100 pmol of each ?rimer, 1 gg of template DNA (cosmid pS1 carrying the eryA segment from Sac. erythraea strain NRRL 2338), and 2.5 units of Thermus aquaticus DNA polymerase in a 100 ml volume of PCR buffer [50 mM KC1, 10 mM TrisHCl (pH 8.0) 2 mM MgCl 2 0.01% gelatin) containing 200 mM of the 4 dNTPs. The above reagents are from Perkin Elmer Cetus, Norwalk, CT. The reaction mixture is overlaid with a drop of paraffin oil and subjected to 30-50 cycles. Each cycle consists of one 94 oC, one 55 OC and one 72 OC period, each of the duration of 3 min. The progress of the amplification is monitored by 1 0 agarose gel-electrophoresis. The PCR primers described in the examples below are derived from the nucleotide sequence of eryA of FIG. 2.

Gene replacement and gene conversion Protoplasts of Sac. erythraea strains are prepared and transformed 1 5 with miniprep DNA isolated from E. coli according to published procedures (Yamamoto et al., 1986). Integrative transformants, in the case of pWHM3 derivatives, are selected after one round of non-selective growth of the primary ThR transformants as described by W( et. al, Gene. 68: 173 (1988). Loss of the ThR phenotype is monitored by plating serial dilutions of a ThR integrant on non-selective medium, followed by replica-plating on thiostrepton-containing medium. ThS (thiostreptonsensitive) colonies arise at a frequency of 10- 2 (Donadio et al., 1990). The retention of the mutant allele is established by Southern hybridization of a few ThS colonies.

A few hundred ThR colonies obtained by transformation of an eryA strain with pWHM4 derivatives are screened for antibiotic production by the agar-plug assay employing Staphylococcus aureus as ThR organism as described (Tuan et al.,Gene, 90: 21 (1990)). The frequency of gene conversion between a 5 kb segment of homologous sequence and a strain carrying a small deletion is >25% (Tuan et al.,Gene. 90: 21 (1990)). Colonies found to produce antibiotic activity are inoculated in SGGP (Yamnamoto et al., 1986), protoplasts are prepared, and the regenerated protoplasts are scored for loss o' the plasmid by replica-plating on non-selective medium.

ThS colonies are then rechecked for antibiotic production, and six producers are analyzed on Southern blots.

WO 93/13663 PCT/US92/00427 12 Fermentation Sac. erythraea cells are inoculated into 100 ml SCM medium soluble starch, 2.0% Soytone [Difco], 0.15% Yeast Extract [Difco], 0.01% CaCl2) and allowed to grow at 32 0 C for 3 to 6 days. The entire culture is then inoculated into 10 liters of fresh SCM medium. The fermenter is operated for a period of 7 days at 320C maintaining constant aeration and pH at 7.0. After fermentation is complete, the cells are removed by centrifugation at 4 0 C and the fermentation beer is kept in the cold until further use.

1 0 The present invention will now be illustrated, but is not intended to be limited, by the following examples: Example 1 Construction of plasmid pABX9 The 9.6 kb BamHI-XhoI segment comprised between sequence coordinates 21.96 and 31.52 was isolated from cosmid pS1 and ligated to SalI-digested pUC19 DNA. The resulting mixture contained the desired plasmid pABX9.

Example 2 Construction of E. coli K12 DH5a/pABX9 Approximately 10 ng of plasmid pABX9, prepared as described in 2 5 Example 1, were transformed into E. coli K12 DH5a and a few of the resulting white ApR colonies that appeared on the LB-agar plates containing X-gal and ampicillin were analyzed for their plasmid content.

One colony was found to carry pABX9, as verified by the observation of fragments of 3.93, 3.39, 2.01, 1.56, 0.87, and 0.48 kb in size upon agarose gel 3 0 electrophoresis after Smal digestion of the plasmid.

Example 3 Construction of plasmid pABX9DN 3 5 Plasmid pABX9, isolated from E. coli K12 DH5a/pABX9, was digested with NcoI and then treated with T4 DNA ligase. The resulting mixture contained the desired plasmid pABX9DN.

WO 93/13663 PCT/US92/00427 13 Example 4 Construction of E. coli K12 DH5a/pABX9DN Approximately 10 ng of plasmid pABX9DN, prepared as described in Example 3, were transformed into E. coli K12 DH5a and a few of the resulting white ApR colonies that appeared on the LB-agar plates containing X-gal and ampicillin were analyzed for their plasmid content.

Colonies carrying pABX9DN exhibited a single NcoI fragment of 11.5 kb visible by agarose gel electrophoresis, confirming that the 813 bp NcoI 1 0 NcoI fragment from pABX9 has been deleted in pABX9DN.

Example Construction of plasmid 1 5 Plasmid pABX95DN was digested with EcoRI and Hindu and ligated to pWHM3 digested with the same two enzymes. The resulting mixture contained the desired plasmid Example 6 Construction of E. coli K12 DH5a/pABX95DN Approximately 10 ng of plasmid pABX95DN, prepared as described in Example 5, were transformed into E. coli K12 DH5a and a few, of the resulting white ApR colonies that appeared on the LB-agar plates containing X-gal and ampicillin were analyzed for their plasmid content.

Colonies carrying pABX95DN exhibited fragments of 8.8 and 7.2 kb visible in agarose gels after EcoRI end Hindl digestion.

Example 7 3 0 Construction of Sac. erythraea AKR5 carrying the eryAKR5 allele by gene replacement Approximately 1 mg of plasmid pABX95DN, isolated from E. coli K12 DH5a/pABX95DN, was transformed into Sac. erythraea NRRL 2338 3 5 and stable ThR colonies were isolated. Serial dilutions of one of these colonies were screened for the loss of the antibiotic resistance marker and total DNA from 5 ThS colonies as well as from untransformed Sac.

t ~erythraea NRRL 2338 was digested with StI and analyzed by Southern ir WO 93/13663 PCT/US92/00427 14 hybridization employing the 0.8 kb SalI fragment between sequence coordinates 24.26 and 25.06 (from pABX9) as probe. Whereas NRRL 2338 showed one SstI band of 3.7 kb that hybridized to the probe, samples from four of the ThS strains exhibited a SstI-hybridizing band of 6.1 kb indicating the presence of the mutant allele. One of these colonies was kept and designated strain AKR5. It carries a deletion of 813 bp in the segment of eryA and is designated the eryAKR5 allele.

Example 8 1 0 Isolation. purification and properties of 5-oxo-5,6-dideoxy-3-a-mycarosyl erythronolide B from Sac. erythraea A 10-liter fermentation of Sac. erythrea AKR5 carrying the allele in a Biolafitte fermentor using SNC Media. The fermentor was 1 5 inoculated with 100 ml of a 3 day old seed. The pO2 was initially 80 ppm and the temperature was maintained at 32 0 C. The pH was controlled to 0.2 by addition of propionic acid or potassium hydroxide as needed.

At harvest (3 days), the whole broth was extracted three times with 4-liter portions of ethylacetate. The combined extracts were concentrated under reduced pressure and the residue was chromatographed on a column (50 x cm) of silica gel packed and loaded in toluene and eluted with a stepwise gradient of increasing concentration of isopropanol in toluene. Fractions were analyzed by TLC and spots were detected by spraying with anisaldehyde sulfuric acid spray reagent and heating. A major component giving blue colored spots eluted with approximately 7% isopropanol.

Fractions containing this material were combined and concentrated to a residue (800 mig). This was further chromatographed on a column (100 x 3 cm) of Sephadex LH-20 in chloroform-heptane-ethanol, 10:10:1, v/v/v.

Fractions were analyzed as above, early fracHons (9-13) yielded 5,6-dideoxy- 3 0 3-a-mycarosyl-5-oxoerythronolide B (45 mg) which was crystallized from heptane/ethylacetate mixture to mp 163-164 OC.

^i'

I~

WO 93/13663 PCT/US92/00427 CMR spectrum in CDCl3 (ppm downfield from TMS) 8.6 9.9 9.9 10.4 14.5 15.2 17.1 17.7 25.3 25.5 37.9 38.7 40.4 40.7 43.3 45.8 46.8 48.9 66.5 69.4 70.0 76.2 76.4 80.4 100.4 175.8 210.8 217.7 Structure was determined by single crystal X-ray diffraction.

Later fractions (15-17) yielded 5,6-dideoxy-5-oxoerythronolide B mg) and still later fractions yielded 5,6-dideoxy-6,6a-epoxy-5oxoerythronolide B (2.8 mg).

Example 9 Construction of plasmid pALeryAKR2 The 1.3 kb DNA segment comprised between coordinates 8.63-9.93 (fragment 1) is amplified by PCR employing two oligodeoxynucleotides, la (5'-GGGAGCATGCTCTCGGTGCGCGGCGGCCGC-3') and lb GCCCTGCAGCGCGTACTCCGAGGTGGCGGT-3'). Similarly, the 1.3 kb DNA segment between coordinates 9.99-11.26 (fragment 2) is PCRamplified employing primers 2a TGGTCTGCAGGCGAGGCCGGACACCGAGG-3') and 2b GGAAGAAGTCAAAGTTCCTCGGTCCCTCT-3'). After digestion with SphI PstI (fragment 1) and PstI EcoRI (fragment the two fragments are ligated to EcoRI SphI-digested pWHM3. The resultant mixture contains the desired plasmid pALeryAKR2.

WO 93/13663 PCT/US92/00427 16 Example Construction of E. coli K12 DH5a/pALeryAKR2 Approximately 10 ng of plasmid pALeryAKR2, prepared as described in Example 9, are transformed into E. coli K12 DH5a and a few of the resulting white ApR colonies that appear on the LB-agar plates containing X-gal and ampicillin are analyzed for their plasmid content.

The identity of plasmid pALeryA2KR2, 9.8 kb in size, and carrying a 2.6 kb EcoRI-Sphl insert with an internal PstIsite, is verified by SaI digestion 1 0 (fragments at 2.91, 2.21, 1.61, 1.42, 1.08, 0.29, 0.12 and 0.10 kb are released, visible by agarose gel electrophoresis). pALeryAKR2 contains an in-frame deletion of 102 base pairs of the corresponding segment of the wild type eryA chromosomal DNA. The cloned segment in pALeryAKR2 is designated the eryAKR2 allele.

Example 11 Construction of Sac. erytbraea AKR2 carrying the eryAKR2 allele by gene replacement Approximately 1 mg of plasmid pALeryAKR2, isolated from E. coli K12 DH5a/pALeryAKR2, is transformed into Sac. erythraea protoplasts and stable ThR colonies are isolated. Serial dilutions of one of these colonies are screened for loss of the antibiotic resistance marker, and six ThS colonies are analyzed for their genotype by Southern hybridization.

2 5 Total DNA from the six ThS colonies and from untransformed Sac.

erythraea NRRL2338 is digested with PstI and with Sa1 and is then examined by Southern hybridization using the 2.6 kb EcoRI-SphI insert from pALeryAKR2 as probe. Whereas NRRL2338 contains a 39 kb PstI hybridizing band, colonies in which the mutation in KR2 has been 3 0 introduced (strain AKR2) exhibit two bands of approximately equal intensity, one at 27 kb and the other at 12 kb. The SalI digest, wh bands at 1.04, 0.75, 0.29, 0.12 and 0.10 kb common to NRRL2338 and AKR2, but with the 1.16 kb band in NRRL2338 replaced by the 1.06 kb band in AKR2, confirms that the only change introduced into strain AKR2 is the deletion 3 5 of the 102 bp segment from KR2, resulting in a strain carrying the eryAKR2 allele.

i II:; ii 1IL1 WO 93/13663 PCT/US92/00427 17 Example 12 Isolation and purification of 11-deoxy-11-oxoerythromycin A The fermentation beer of strain AKR2, cooled to?4°C is adjusted to pH 8.0 and is extracted sequentially with three equal volumes of methylene chloride. The combined methylene extracts are concentrated to an oily residue and partitioned between heptane and methanol. The methanol layer is removed, washed once with heptane and concentrated to a residue. The residue is digested in methylene chloride and washed 1 0 once with potassium phosphate buffer pH 7.8 and once with water. The methylene chloride layer is concentrated to a residue and digested in the lower phase v/v/v) of a carbon tetrachloride; methanol; aqueous phosphate buffer (0.05 M, pH 7.0) system and chromatographed on an Ito Coil Planet Centrifuge in the same system. Fractions containing the 1 5 desired 11-oxo-11-deoxyerythromycin A were combined, concentrated, digested in methylene chloride, washed well with water and concentrated on rotary evaporator under reduced pressure to yield 11-deoxy-11oxoerythromycin A as an off-white solid froth. Its identity is confirmed by comparison with antibiotic L53-18A. 11-Deoxy-ll-oxoerythromycin A is dissolved in tetrahydrofuran and the solution is diluted with an equal volume of water. This is then acidified to pH 4.0 and allowed to stand at room temperature for 4 hours. The pH is adjusted to 9.0 and the solution i is diluted with an equal volume of water and extracted with two volumes i of methylene chloride. The combined methylene chloride extracts were 2 5 evaporated to dryness under reduced pressure to yield antibiotic L53-18A as a white solid.

Example 13 Construction of plasmid pALeryADH4 Primers 3a (GCGCGAGCTCGACGACCAGGGCGGCATGGT) and 3b (GGTGGCATGCTGCGACCACTGCGCGTCGGC) are used to PCR-amplify the 1.05 kb eryA segment of the Sac. erythraea chromosome between sequence coordinates 18.47-20.07 (fragment and primers 4a (AGCTGCATGCTCTGGACTGGGGACGGCTAG) and 4b (CGCGGGATCCCAGCTCCCACGCCGATACCG) are used to amplify the I 1.35 kb segment between sequence coordinates 20.58-21.96 (fragment 4) as described in Example 1. Fragment 3 and 4, after digestion with SstI SphI t tsuKuvaensis, )rrepromyces griseus, streptomyces mycarojasciens, Streptomyces platensis, Streptomyces venezuelae, Streptomyces WO 93/13663 PCT/US92/00427 18 and with SphI BamHI, respectively, are ligated to SstI BamHI-digested pWHM3. The resulting ligation mixture contains the desired plasmid pALeryADH4.

Example 14 Construction of E. coli K12 DH5a/pALeryADH4 Approximately 10 ng of pALeryADH4, prepared as described in Example 13, are transformed transformed into E. coli K12 DH5a, and a few 1 0 of the resulting white ApR colonies that appear on the LB-agar plates containing X-gal and ampicillin are analyzed for their plasmid content.

The identity of plasmid pALeryADH4, 9.6 kb in size, is verified by SphI EcoRI digestion (fragments at 7.2, 1.35 and 1.05 kb are released).

pALeryADH4 carries a 498 base pair in-frame deletion of the 1 5 corresponding segment of the wild type eryA DNA. The cloned segment in pALeryADH4 is designated the eryADH4 allele.

Example Construction of Sac. erythraea ADH4 carrying the eryADH4 allele by gene replacement Approximately 1 mg of plasmid pALeryADH4, isolated from E. coli K12 DH5a/pALeryADH4, is used for transformation into Sac. erythraea protoplasts and stable ThR colonies are isolated. Serial dilutions of one of 2 5 these colonies are screened for loss of the antibiotic resistance marker, and six ThS colonies are analyzed for their genotype by Southern hybridization. Total DNA from the six ThS colonies and from untransformed Sac. erythraea NRRL2338 is digested with SphI and with SstI and examined by Southern hybridization using the 2.4 kb SstI-BamHI insert from pALeryADH4 as probe. Strains in which the wild type allele has been replaced by the mutated copy show two SphI bands, one at 13.5 kb and the other at 12.4 kb, whereas the wild type strain exhibits a single band at 26 kb. The SstI pattern, with the 2.9 kb band from NRRL2338 being replaced in ADH4 by a 2.5 kb band, confirms that the 487 bp deletion created in plasmid pALeryADH4 has been transferred into the chromosome of ADH4. Strains that carry the eryADH4 allele in place of J the wild type sequence are designated Sac. erythraea ADH4.

I ii Ii WO 93/13663 PCr/US92/00427 19 Example 16 Isolation and characterization of 7-hydroxyerythromycin A and 6-deoxy-7hydroxyerythromycin A The fermentation beer of strain ADH4 is cooled to 4 0 C and the pH is adjusted to 5.0. The mixture is extracted once with an equal volume of methylene chloride. The pH of the aqueous layer is readjusted to 9.0 and two further methylene chloride extracts are carried out. These two extracts are combined, washed with water and concentrated to a residue. This is 1 0 digested in 10 ml of the upper phase of a v/v/v) mixture of hexane, ethylacetate, aqueous phosphate buffer (0.05 M, pH 7.5) and chromatographed on an Ito Coil Planet Centrifuge in the same system.

Fractions containing the desired 7-hydroxyerythromycin were combined, concentrated, and partitioned between methylene chloride and dilute (pH 1 5 9.5) ammonium hydroxide solution. Fractions containing the desired 6deoxy-7-hydroxyerythromycin were combined, concentrated, and partitioned between methylene chloride and dilute (pH 9.5) ammonium hydroxide solution. The methylene chloride layers are washed with water and then concentrated to yield the desired 7-hydroxyerythromycin A and 6-deoxy-7-hydroxyerythromycin A as white foams.

Example 17 Construction of plasmid pALeryAKS1 The 1.4 kb segment of eryA between sequence coordinates 1.11-2.54 (fragment 5) and the 1.5 kb segment between sequence coordinates 2.88- 4.37 (fragment 6) are PCR-amplified using primers (TGCAGAATTCGCTGGCCGCGCTCTGGCGCT) and (GAGAGCTGCAGCATGAGCCGCTGCTGCGGG), and 6a (CATGCTGCAGGACTTCAGCCGGATGAACTC) and 6b (GAGGAAGCTTCCAGCCGGTCCAGTTCGTCC), respectively, as described in Example 9. After digestion with EcoRI PstI (fragment 5) and PstI Hindm (fragment the two fragments are ligated to EcoRI HindIldigested pWHM3. The resulting mixture contains the desired plasmid 3 5 pALeryAKS1.

WO 93/13663 PCT/US92/00427 Example 18 Construction of E. coli K12 DH5a/pALeryAKS1 Approximately 10 ng of pALeryAKS1, prepared as described in Example 17, are transformed into E. coli K12 DH5a, and a few of the resulting white ApR colonies that appear on the LB-agar plates containing X-gal and ampicillin are analyzed for their plasmid content. The identity of plasmid pALeryAKS1, 10.1 kb in size, is verified by digestion with PstI HindI (fragments of 8.6 and 1.5 kb are observed by agarose gel 1 0 electrophoresis) and with SalI (fragments of 2.93, 2.21, 1.42, 1.37, 0.86, 0.54, 0.27, 0.14, 0.13, and 0.10 kb are observed). pALeryAKS1 carries an in-frame deletion of 282 base pairs of the corresponding wild type eryA DNA. The cloned insert in plasmid pALeryAKS1 is designated the eryAKS1 allele.

Example 19 Construction of Sac. erythraea AKS1 carrying the eryAKS1 allele by gene replacement Approximately 1 mg of plasmid pALeryAKS1, isolated from E. coli K12 DH5a/pALeryAKS1, is used for transformation into Sac. erythraea protoplasts and stable ThR colonies are isolated. Serial dilutions of one of these colonies are screened for loss of the antibiotic resistance marker, and six ThS colonies are analyzed for their genotype by Southern hybridization. Total DNA from the six ThS colonies and from untransformed Sac. erythraea NRRL2338 is digested with PstI and with SmaI and examined in Southern hybridization employing the 2.9 kb EcoRI-Hindl insert from pALeryAKS1 as probe. Colonies in which the wild type allele has been replaced by the mutated copy (strain AKS1) show two PstI bands, one at 34.5 and the other at 4.4 kb, whereas the wild type 3 0 strain exhibits a single band at 39 kb. The SnaI pattern, with the 2.9 kb band from NRRL2338 being replaced in AKS1 by a 2.6 kb band, confirms that the 282 bp created in plasmid pALeryAKS1 has been transferred into strain AKS1. Strains that carry the eryAKS1 allele are designated Sac.

erythraea AKS1.

WO 93/13663 PCT/US92/00427 21 Example Synthesis of (2S.3R.4S,5S)35-dihydroxy-2,4-dimethylhexanoic acid n-butyl thioester A convenient source of this compound in chiral purity is the antibiotic oleandomycin. Oleandomycin (5 g) is dissolved in an aprotic solvent such as toluene and treated with diazabicyclo[5.4.0]undecene-5 (1 g) and heated for one hour. The resulting solution is poured into iced water, agitated well and the organic layer is drawn off and concentrated to 1 0 a residue. The residue is digested in methylene chloride and treated exhaustively with a solution of ozone. The resulting ozonide is oxidatively decomposed with dilute hydrogen peroxide in sufficient aqueous ethanol to yield a monophasic mixture. This is further diluted with water and made 0.1 N with sodium hydroxide. The mixture is 1 5 warmed for one hour at 70 0 C and then cooled before being acidified to pH 2.5 with dilute sulfuric acid. The mixture is then exhaustively extracted with methylene chloride. The combined extracts are concentraL.. to an oily residue and the desired lactone is recovered by chromatography on silica gel eluted with a gradient of tolueneisopropanol.

The 8-lactone is converted to the butyl thioester before feeding to I Sac, erythrea AKS1 by refluxing with n-butylthiol in the presence of a catalytic amount of triethylamine.

2 5 Example 21 Isolation of (14S,15S)14(1-hydroxyethyl)erythromycin A The fermentation broth of AKS1 is cooled to 4 0 C and adjusted to pH and extracted onct with methylene chloride. The aqueous layer is 3 0 readjusted to pH 9.0 and extracted twice with methylene chloride and the combined extracts are concentrated to a solid residue. This is digested in methanol and chromatographed over a columxt of Sephadex LH-20 in methanol. Fractions are tested for bioactivity against a sensitive organism, such as Staphylococcus aureus ThR, and active fractions are combined.

3 5 The combined fractions are concentrated and the residue is digested in ml of the upper phase of a solvent system consisting of n-heptane, benzene, acetone, isopropanol, 0.05 M, pH 7.0 aqueous phosphate buffer (5:10:3:2:5, and chromatographed on an Ito Coil Planet i i .i i ~1 il WO 93/13663 PC/US92/00427 22 Centrifuge in the same system. Active fractions are combined, concentrated and partitioned between methylene chloride and dilute ammonium hydroxide (pH The methylene chloride layer is separated and concentrated to yield the desired product as a white foam.

Example 22 Construction of plasmid pALeryAKS2 Primers 7a (CGCCCGAATTCGAGGCGCTGGGCGCCCGGAC) and 7b 1 0 (CCACCTGCAGCGCGGGACCTTCCAGCCCC), and primers 8a (GTGGGTCGCTGCAGACGGTGACTGCGG) and 8b (GGTC AAGCTTCGTCGGCGAGCAGCTTCTC) are used to PCR-amplify the 1.45 kb eryA segment between sequence coordinates 5.71-7.16 (fragment 7) and the 1.5 kb eryA segment between sequence coordinates 1 5 7.22-8.70 (fragment respectively. After digestion with EcoRI PstI (fragment 7) and with PstI Hind (fragment the two fragments are ligated to pWHM3 cut with EcoRI HindIII. The resulting mixture ns the desired plasmid pALeryAKS2.

Example 23 Construction of E. coli K12 DH5a/pALeryAKS2 Approximately 10 ng of pALeryAKS2, prepared as described in Example 22, are transformed into E. coli K12 DH5a, and a few of the resulting white ApR colonies that appear on the LB-agar plates containing X-gal and ampicillin are analyzed for their plasmid content. The identity of plasmid pALeryAKS2, 10.1 kb in size, is verified by digestion with PstI HindI (fragments of 8.6 and 1.5 kb are observed by agarose gel electrophoresis) and with SstII (fragments of 4.0, 2.3, 2.0, 0.72, 0.43, 0.40, 3 0 0.20, 0.18, 0.13 and 0.11 kb observed). Plasmid pALeryAKS2 carries an inframe deletion of 60 base pairs of the corresponding wild type eryA DNA.

This deletion removes the active site cysteine from KS2. The cloned insert in plasmid pALeryAKS2 is designated the eryAKS2 allele.

-1 WO 93/13663 PC/US92/00427 23 Example 24 Construction of Sac. erythraea AKS2 carrying the eryAKS2 allele by gene replacement Approximately 1 mg of plasmid pALeryAKS2, isolated from E. coli K12 DH5a/pALeryAKS2, is used for transformation into Sac. erythraea protoplasts and stable ThR colonies are isolated. Serial dilutions of one of these colonies are screened for loss of the antibiotic resistance marker, and six ThS colonies are analyzed for their genotype by Southern 1 0 hybridization. Total DNA from the six ThS colonies and from untransformed Sac. erythraea NRRL2338 is digested with PstI and with SstII and examined in Southern hybridization employing the 2.9 kb EcoRI- HindII insert from pALeryAKS2 as probe. Colonies in which the wild type allele has been replaced by the mutated copy (strain AKS2) show two PstI 1 5 bands, one at 34.5 and the other at 4.4 kb, whereas the wild type strain exhibits a single band at 39 kb. The SstII pattern, with the 0.78 kb band from NRRL2338 being replaced in AKS2 by a 0.72 kb band, confirms that the 60 bp created in plasmid pALeryAKS2 has been transferred into strain AKS2. Strains that carry the eryAKS2 allele are designated Sac. erythraea AKS2.

Example Synthesis of (2R,3R,4S,5R)2.4-dimethyl-3-fluoro-5-hydroxyhexanoic acid nbutyl thioester (2R,3S,4S,SR)3,5-Dihydroxy-2,4-dimethylhexanoic acid-&-lactone (1 g) from Example 20 is digested in 10 ml of pyridine and treated with ptoluenesulfonyl chloride (1.3 g) and allowed to stand at room temperature overnight. The mixture .s poured into iced water and extracted with 3 0 methylene chloride and the methylene chloride is concentrated to the crude sulfonate ester. This is digested in acetonitrile (100 ml) and heated under reflux after the addition of tetrabutylammonium fluoride (1.75 g).

After 6 hours the mixture is cooled, poured over iced water (300 ml) and extracted three times with 200 ml portions of methylene chloride. The combined methylene chloride extracts were concentrated and the residue was chromatographed on a column of silica gel eluted with a stepwise gradient of isopropanol (0 to 50%) in toluene, P~-ctions containing (2R,3R,4S,5R)2,4-dimethyl-3-fluoro-5-hydroxyhexanoic acid_d-lactone were I j WO 93/13663 PCT/US92/00427 24 combined and concentrated to a white solid. The lactone is then converted to the n-butyl thiolester by refluxing in n-butyl thiol with a catalytic amount of triethylamine. Solvent is removed and the residue is digested in DMSO before feeding to fermentations of Sac. erythraea AKS2.

Example 26 Isolation and purification of 11-epifluoro-15-norerythromycin A The fermentation broth of strain AKS2 is cooled to 4 0 C and adjusted to pH 4.0 and extracted once with ethylacetate. The aqueous layer is adjusted to pH 9.0 and extracted twice with methylene chloride and the combined extracts are concentrated to a white solid. This is chromatographed over a column of Sephadex LH-20 in a mixture of heptane, chloroform, ethanol (10:10:1, v/v/v) and fractions containing the 1 5 desired product are combined and concentrated to a solid residue. This is further purified by countercurrent chromatography on an Ito Coil Planet Centrifuge on a system composed of carbon tetrachloride; methanol; 0.05 M; pH 7.0 aqueous potassium phosphate buffer Fractions containing the desired 11-epifluoro-15-norerythromycin were combined, 2 0 and concentrated to a residue. This was digested in methylene chloride and dilute (pH 9.5) ammonium hydroxide and the methylene chloride layer was separated, washed with water and concentrated to yield the desired 11-epiiuoro-15-norerythromycin A as white solid.

Example 27 Construction of plasmid pALeryAM4.1 Primers 9a (GCGCCGAATTCTCGAGACGGCGTGGGAGGCA) and 9b (TTGCGGTACCAGTAGGAGGCGTCCATCGCG) are employed to PCR- 3 0 amplify the 2.0 kb eryA segment between sequence coordinates 17.35-19.38 (fragment After digestion with EcQPJ KpnI, fragment 9 is ligated to pUC19 cut with the same two enzymes The resulting mixture contains the desired plasmid pALeryAM4.1.

WO 93/13663 PCT/US92/00427 Example 28 Construction of E. coli K12 DH5a/pALeryAM4.1 Approximately 10 ng of pALeryAM4.1, prepared as described in Example 27, are transformed into E. coli K12 DH5a, and a few of the resulting white ApR colonies that appear on the LB-agar plates containing X-gal and ampicillin are analyzed for their plasmid content. The identity of plasmid pALeryAM4.1, 4.7 kb in size, is verified by digest:o., with Sail (fragments of 2.8, 0.85, 0.53, 0.27 and 0.22 kb are observed by ise, gel electrophoresis).

Example 29 Construction of plasmid pALeryAM4.2 Primers 10a (GCTGGGATCCCGCGGCGCGGGTTGCAGCAC) and (CGGAACTCGGTGAGCATGCCGGGACTGCTC) are used to PCRamplify the 2.1 kb eryA segment between sequence coordinates 21.94-24.00 (fragment 10). The 2.6 kb fragment KpnI(96)-BamHI(102) from cosmid clone pR1, and fragment 10 cut with BamHI SphI, are ligated to pALeryAM4.1 cut with KpnI 5phI. The resulting mixture contains the desired plasmid pALeryAM4.2.

Example Construction of E. coli K12 DH5a/pALeryAM4.2 Approximately 10 ng of pALeryAM4.2, prepared as described in Example 29, are transformed into E. coli K12 DH5a, and a few of the resulting white ApR colonies that appear on the LB-agar plates containing X-gal and ampicillin are analyzed for their plasmid content. The identity of plasmid pALeryAM4.2, 9.3 kb in size, is verified by digestion with Xhol hl (to ensure that the entire 6.65 kb insert is released) and with Sail, with fragments of 2.8, 1.82, 1.09, 0.94, 0.85, 0.75, 0.45, 0.27, 0.22 and 0.13 kb are observed by agarose gel electrophoresis).

1 L WO 93/13663 PCT/US92/00427 26 Example 31 Construction of plasmid pALeryAM1 The 2.9 kb SmaI(4)-SmaI(20) fragment from cosmid clone pR1 is ligated to pUC12 cut with Smal. The resulting mixture contains plasmid pALeryAM1.

Example 32 Construction of E. coli K12 DH5aa/pALeryAM1 Approximately 10 ng of pALeryAM1, prepared as described in Example 31, are transformed into E. coli K12 DH5o, and a few of the resulting white ApR colonies that appear on the LB-agar plates containing X-gal and ampicillin are analyzed for their plasmid content. The identity 1 5 of plasmid pALeryAM1, 5.6 kb in size, is verified by digestion with SmaI (the 2.9 kb insert is realeased) and with SphI, with release of one 4.4 and one 1.07 kb bands. Both orientations of the insert in plasmid pALeryAM1 are useful.

Example 33 Construction of plasmid pALeryAM4.3 Plasmid pALeryAM1 is cut with XhoI to completion, partially with phI, and the resulting 5.25 kb band, isolated from an agarose gel, is ligated 2 5 to the 6.65 kb insert released from pALeryAM4.2 by XhoI SphI digestion The resulting mixture contains the desired plasmid pALeryAM4.3.

Example 34 Construction of E. coli K12 DH5a/pALeryAM4.3 Approximately 10 ng of pALeryAM4.3, prepared as described in Example 33, are transformed into E. coli K12 DH5, and a few of the resulting white ApR colonies that appear on the LB-agar plates containing X-gal and ampicillin are analyzed for their plasmid content. The identity 3 5 of plasmid pALeryAM4.1, 11.9 kb in size, is verified by Xhol SphI digestion (fragments of 6.65 and 5.25 kb are visible by agarose gelelectrophoresis). Plasmid pALeryAM4.3 carries the entire eryA module 4 WO 93/13663 PCT/US92/00427 27 inserted into the KS region of module 1. The cloned insert in pALeryAM4.3 is degnated the eryAM412 allele.

Example Construction of plasmid pALeryAM4.4 Plasmid pALeryAM4.3 is cut with EcoRI Hindm, and the resulting 9.2 kb band, recovered from an agarose gel, is ligated to pWHM4 cut with the same two enzymes. The resulting mixture contains the 1 0 desired plasmid pALeryAM4.4.

Example 36 Construction of E. coli K12 DH5a/pALeryAM4.4 1 5 Approximately 10 ng of pALeryAM4.4, prepared as described in Example 35, are transrjrmed into E. coli K12 DH5a, and a few of the resulting white ApR colonies that appear on the LB-agar plates containing X-gal and ampicillin are analyzed for their plasmid content. The identity of plasmid pALeryAM4.1, 16.5 kb in size, is verified by EcoRI HindIII digestion, with fragments of 9.2 and 7.3 kb released. Plasmid pALeryAM4.4 carries the eryAM412 allele on the Sac. erythraea multicopy vector pWHM4.

Example 37 Construction of Sac. erythraea AM412 carrying the eryAM412 allele by gene conversion Approximately 1 mg of plasmid pALeryAM4.4, isolated from E. coli K12 DH5a/pALeryAM4.4, is used for transformation into Sac. erythraea strain AKS1 protoplasts. A few hundred transformants are screened for antibiotic production by the agar-plug assay, and one of the colonies found to produce antimicrobial activity is cured of pALeryAM4.4 by protoplast formation and regeneration as described in General Methods. Total DNA from six antibiotic-producing, ThS colonies (strain AM412)and from strain AKS1 is digested with SphI and with XhoI and the resulting Southern blot is hybridized first to the 2.9 kb insert from pALeryAM1, and then to the 2.9 kb SstI(95)-SsI(101) fragment from plasmid pALeryAM4.2. With the first probe, the SphI band at 0.8 kb in strain AKS1 is seen to be replaced by a WO 93/13663 PC/US92/00427 28 kb band in strain AM412, whereas the other two bands at 2.4 kb and 5.2 kb are unaffected. In the Xhol digest, the AKS1 band at 2.9 kb is replaced by a 9.6 kb band in AM412, with the other band at 5.2 kb conserved in both strains. Using the SstI(95)-SstI(101) fragment as probe, strain AKS1 exhibits one band at 25.5 kb iad one at 17.9 kb in the SphI and XhoI digests, respectively, whereas, in addition to these bands, strain AM412 shows one SphI band at 7.5 kb and one XhoI band at 9.6 kb. In this way, it is established that the eryAKS1 allele has been converted into the eryAM412 allele in strain AM412.

Example 38 Isolation and purification of 14-(1-propyl)erythromycin A At harvest the fermentation is adjusted to pH 9.5 and extracted 1 5 twice with equal volumes of methylene chloride. The combined extracts are washed once with water and concentrated to an oily residue. This is partitioned in a heptane methanol water v/v/v) system and the lower layer is washed once with heptane and then concentrated to a semisolid residue. This is digested in methanol and chromatographed over a column of Sephadex LH-20 in methanol. Fractions are tested for bioactivity in an agar diffusion assay on plates seeded with the macrolidesensitive strain Staphylococcus aureus ThR. Active fractions are combined and further purified by chromatography over silica gel a chloroform:methanol gradient containing 0.1% triethylamine. Fractions containing the desired 14-(1-propyl)erythromycin A are combined and concentrated to yield the product as a white solid.

Example 39 Construction of plasmid pALeryAM5.1 The 4.7 kb eryA fragment between sequence coordinates 23.65-28.36 (fragment 11) is PCR-amplified employing primers 11a (ATGCTCGAGATCTCGTGGGAGGCGCTGGA) and 11b (AGAACTCGGTGAGCATGCCCGGGCCCGCCA). Fragment 11, after 3 5 digestion with XhoI SphI, is ligated to the 5.25 kb fragment resulting from complete XhoI and partial SphI digestion of pALeryAM1, as in Example 33. The resulting mixture contains the desired plasmid pALeryAM5.1.

WO 93/13663 PCT/US92/00427 29 Example Construction of E. coli K12 DH5a/pALeryAM5.1 Approximately 10 ng of pALeryAM5.1, prepared as described in Example 39, are transformed into E. o LK12 DH5a, and a few of the resulting white ApR colonies that appear on the LB-agar plates containing X-gal and ampicillin are analyzed for their plasmid content. The identity of plasmid pALeryAM5.1, 9.95 kb in size, is verified by Sph. XhoI 1 0 digestion, with fragments of 5.25 and 4.7 kb released, and by SmiaI digestion where fragments of 3.39, 2.68 and 1.94 (doublet) kb are observed.

Plasmid pALeryAM5.1 carries the entire eryA module 5 inserted into the V3-ketoacyl ACP synthase region of modulel. The cloned insert in plasmid pALeryAM5.1 is designated the eryA512 allele.

Example 41 Construction of plasmid pALeryAM5.2 Plasmid pALeryAM5.1 is cut with EcoRI Hindi and the resulting 6.3 kb fragment, recovered from an agarose gel, is ligated to pWHM4 cut with the same two enzymes. The resulting mixture contains the desired plasmid pALeryAM5.2.

Example 42 Construction of E. coli K12 DH5a/pALeryAM5.2 Approximately 10 ng of pALeryAM5.2, prepared as described in Example 41, are transformed into E. coi K12 DH5a, and a few of the resulting white ApR colonies that appear on the LB-agar plates containing X-gal and ampicillin are analyzed for their plasmid content. The identity.

of plasmid pALeryAM5.2, 13.6 kb in size, is verified by digestion with EcoRI Hindm, with fragments of 7.3 and 6.3 kb released. Plasmid pALeryAM5.2 contains the eryAM512 allele on the Sac. erythraea multicopy vector pWHM4.

I

W6 93/13663 PC~/US92/00427 Example 43 Construction of Sac. erythraea AM512 carrying the eryAM512 allele by gene conversion Approximately 1 mg of plasmid pALeryAM5.2, isolated from E. coli K12 DH5a/pALeryAM5.2, is used for transformation into Sac. erythraea strain AKS1 protoplasts. A few hundred transformants are screened for antibiotic production by the agar-plug assay, and one of the colonies found to produce antimicrobial activity is cured of pALeryAM5.2 by protoplast 1 0 formation and regeneration as described in General Methods. Total DNA Sfrom six antibiotic-producing, Th S colonies (strain AM512)and from strain AKS1 is digested with SphI and with XhoI and the resulting Southern blot is hybridized first to the 2.9 kb insert from pALeryAM1, and then to the 0.8 kb NcoI(119)-NcoI(123) fragment from plasmid pALeryAM5.1. With the 1 5 first probe, the SphI band at 0.8 kb in strain AKS1 is replaced by a 5.5 kb band in strain AM512, whereas the other two bands at 2.4 kb and 5.2 kb are unaffected. In the XhoI digest, the AKS1 band at 2.9 kb is replaced by a 7.6 kb band in AM512, with the other band at 5.2 kb conserved in both strains.

Using the NcoI(119)-NcoI(123) fragment as probe, strain AKS1 exhibits one band at 25.5 kb and one at 17.9 kb in the SphI and XhoI digests, respectively, whereas, in addition to these bands, strain AM512 shows one Sphl band at 5.5 kb and one XhoI band at 7.6 kb. In this way, it is established that the eryAKS1 allele has been converted into the eryAM512 allele in strain AM512.

Example 44 Isolation and purification of 14[1(1-hydroxypropyl)lerythromycin A At harvest the pH of the fermentation of AM512 is adjusted to 3 0 and the mixture is extracted twice with equal volumes of ethylacetate.

The combined ethylacetate extracts are washed with water, dried and partitioned in a heptane, methanol, water v/v/v) system. The lower (methanolic phase) is washed with an equal volume of heptane and is concentrated to a residue. This is chromatographed on a Sephadex LH- 3 5 20 column in methanol and fractions containing the desired 14[1(1hydroxypropyl)]erythromycin A are concentrated and further purified by chromatography on an Ito Coil Planet Centrifuge in a system consisting of n-heptane, benzene, acetone, isopropanol, 0.65 M, pH 7.0 aqueous i I t.

LiU._Cli~ N o 93/13663 PC//US92/00427 31 potassium phosphate buffer (5:10:2:3:5, Fractions containing the desired product are concentrated to a solid residue and partitioned between methylene chloride and dilute (pH 9.5) ammonium hydroxide.

The organic layer is washed with water and concentrated to yield 14[1(1hydroxypropyl)]erythromycin A as a white solid.

Although the present invention is described in the Examples listed above in terms of preferred embodiments, they are not to be regarded as limiting the scope of the invention. The above descriptions serve to 1 0 illustrate the principles and methodologies involved in creating the three types of mutations that can be introduced into the eryA segment of the Sac. erythraea chromosome that result in the synthesis of novel polyketide products. Although single Type I alterations, leading to the production of 5-oxo-5,6,-dideoxy-3a-mycorosyl erythronolide B, 11-oxo-11- 1 5 deoxyerythromycin A, 7-hydroxyerythromycin A, 7-oxo- 7deoxyerythromycin A, 5-desosaminyl-3-oxo-3-deoxyerythronolide A, and A-6,7-anhydro-6-deoxyerythromycin A are specified herein, it is obvious that other Type I changes can be introduced into the eryA segment leading to novel polyketide structures. Among the additional Type I alterations that can be obtained are those in which two or more modules are affected leading to the synthesis of novel polyketides. Examples of combinations of two Type I alterations leading to useful compounds include but are not limited to: mutants of the the P-ketoreductase of module 2 (KR2) and the P-ketoreductase of module 4 (KR4) leading to the formation of 7,11-dioxo-7,11-dideoxyerythromycin A; mutants of KR2 and the P-ketoreductase of module 6 (KR6) leading to the formation of 3,11dioxo-3,11-dideoxy-5-desosaminylerythronolide A; mutants of KR2 and the dehydratase of module 4 (DH4) leading to the synthesis of 7-hydroxy- 11-oxo-11-deoxyerythromycin A; mutants of KR2 and the enoylreductase of module 4 (ER4) leading to the synthesis of A-6,7-anhydro-11-oxo-11deoxyerythromycin A; mutants of KR4 and KR6 leading to the synthesis of 3,7-dioxo-3,7-dideoxy-5-desosaminylerythronolide A; mutants of KR6 and DH4 leading to the synthesis of 3-oxo-3-deoxy-5-desosaminyl-7hydroxyerythronolide A; mutants of KR6 and ER4 leading to the synthesis 3 5 of 3-oxo-3-deoxy-5-desosaminyl-A-6,7-anhydroerythronolide A. Examples of combinations of three Type I alterations leading to the synthesis of novel polyketides include but are not limited to: mutants of KR2, KR4 and KR6 leading to the synthesis of 3,7,11-trioxo-3,7,11-trideoxy-5-

II

WO 93/13663 PCT/US92/00427 32 desosaminylerythronolide A; mutants of KR2, KR6 and DH4 leading to the synthesis of 3,11-dioxo-3,11-dideoxy-5-desosaminyl-7hydroxyerythronolide A; mutants of KR2, KR6 and ER4 leading to the synthesis of 3,11-dioxo-3,11-dideoxy-5-desosaminyl-D-6,7anhydroerythronolide A. All combinations of two or three Type I mutants, the Sac. erythraea strains that carry said combinations and the corresponding polyketides produced from said strains, therefore, are included within the scope of the present invention.

Although the Type II mutants specified herein have been 1 0 constructed in the p-ketc.cyl ACP synthase of module 1 (KS1) and the 3ketoacyl ACP synthase of module 2 (KS2), other Type II mutants can be constructed in other domains to result in the synthesis of novel polyketide structures upon feeding with appropriate substrate analogs.

Other Type II mutants include but are not limited to: inactivatiorn of the 1 5 either of the acyltransferases or acyl carrier proteins of module 1, or the acyltransferase or acyl carrier protein of module 2, the P-ketoacyl ACP synthase, acyltransferase or acyl carrier protein of module 3, module 4 or module 5. Furthermore, compounds other than (2S,3R,4S,5S)3,5dihydroxy-2,4-dimethylhexanoic acid-ethyl thioester and (2S,3S,4S,5S)2,4dimethyl-3-fluoro-5-hydroxyhexanoic acid-ethyl thioester specified herein can be synthesized and fed to strains AKS1 or AKS2 specified herein or other strains that carry other Type II mutations to result in the creation of nov. polyketides that are within the scope of the present invention.

Although two examples of Type III alterations are specified herein, it is apparent to those skilled in the art that many other examples of Type III changes are possible. Strains of Sac. erythraea carrying changes of this type offer the very high potential for the production of novel polyketides of specified structure, since they do not require synthetic substrates as do Type II mutants and they are not limited to the formation of derivatives of erythromycin, as in the case of Type I mutants. In the embodiments of Type III mutants specified herein, we have illustrated how a second copy of a complete module can be introduced at a desired position by gene conversion to result in the synthesis of 14-(1-propyl)erythromycin A or 14- [1(1-hydroxypropyl])erythromycin A. These alterations make use of the 3 5 high conservation and simultaneous lack of specificity of the -ketoacyl ACP synthases of modules I and 2, thereby making possible the i construction of hybrid P-ketoacyl ACP synthase functions consisting of portions of proteins derived from different modules. Those skilled in the U i i ~.1.161 i WO 93/13663 PCT/US92/00427 33 art understand, therefore, that it is possible, as exemplified for KS1 and KS2, to delete a small portion of the P-ketoacyl ACP synthase of other modules and to construct strains carrying such alterations which can then be employed as hosts for introducing at the deleted 3-ketoacyl ACP synthase location a second copy of any homologous module.

Furthermore, as exemplified herein, it is also possible to delete any segment of eryA by ligation of two non-contiguous PCR-generated fragments and to subsequently construct strains, therefore, devoid of any or all portions of any module. Such strains deleted of a full module can be 1 0 employed for reintroduction of either the same or a different module at a different location. It is possible, therefore, to determine the novel structures desired and then create a series of Sac. erythraea strains containing the corresponding arrangements of eryA modules that would produce said novel structures that are included within the scope of the 1 5 present invention. Additional examples of novel compounds produced from the construct of Type III alterations include but are not limited to 11-deoxyerythromycin, resulting from the insertion of the eryA segment encoding DH4 and ER4 in module 2.

Mrceover, it will also be apparent that two or more modules can be excised and introduced into various sites of the Sac. erythraea chromosome to produce novel polyketides of predicted structure such as the introduction of the eryA segment encoding DH4 and ER4 in both module 1 and module 2 to result in the production of 14(R)[1hydroxypropyl]11-deoxyerythromycin A. All combinations, therefore, of 2 5 Type III alterations and the strains of Sac. erythraea that carry said alterations as well as the polyketides produced from said strains are j included within the scope of the present invention.

In addition, it is also possible to create combinations of Type I, Type II and Type EI alterations and insert such alterations into Sac. erythraea to 3 0 produce novel polyketides. Examples of such combinations include but are not limited to the following. The combination of a Type I alteration, such as an alteration in DH4 and a Type II alteration, such as a mutation in the KS1 to result in the formation of (14S,15S)14-[1-hydroxyethyl]-7hydroxyerythromycin A when the strain of Sac. erythraea carrying such 3 5 alterations is fed with the compound (2S,3R,4S,5S)3,5-dihydroxy-2,4dimethylhexanoic acid ethyl ester. The combination of a Type I alteration, such as an alteration in DH4 and a Type III alteration, such as found in Sac. erythraea strain AM412, wherein a copy of the DNA segment of WO93/13663 PCT/US92/00427 34 module 4 is introduced in module 1, such that the Sac. erythraea strain so constructed produces the compound 7-hydroxy-14-propylerythromycin

A.

All combinations of two or more alterations of Type I, Type II and Type I alterations, the Sac. erythraea strains that carry such alterations, and the polyketides produced from such strains are included within the scope of the present invention. It will also occur to those skilled in the art that novel structures can be produced by altering the specificity of the acyltransferase functions in any module. Examples include: replacement of the acyltransferase domains of modules 1, 2, 3, 4, 5,or 6 in eryA with 1 0 those of modules 4, 4, 2, 2, 2, and 4, respectively, to result in the production of 12-epierythromycin A,10-epierythromycin A, 8epierythromycin A, 6-epierythromycin A, 4-epierythromycin A and 2epierythromycin A, respectively, that are included within the scope of the present invention.

It should be emphasized that the introduction of an entire eryA module at a different location, as exemplified for the construction of Sac.

erythraea strains AM412 and AM512 in Examples 29 and 35, respectively, does not rely on homologous recombination between the incoming eryA module and the host chromosome. Rather, gene conversion of the host allele with the eryA allele residing on the multicopy plasmid requires DNA sequences homologous to the host allele flanking the incoming module. Thus, any module carrying the desired specificities, either from homologous or heterologous sources, can be employed in gene conversion of the host allele, provided that is flanked by segments of 2 5 homology. It will occur to those skilled in the art, therefore, that, given the large number of natural polyketide molecules existing, a wide variety of additional novel molecules of predicted structure can be produced in Type III mutants containing an additional module of desired specificities or where an endogenous module is replaced by an exogenous one. The length of the acyl chain can be easily controlled by suitably changing the number of modules involved in its synthesis. Similarly, the introduction of keto, hydroxy, enoyl, or methylene groups at specific points along the acyl chain can be easily achieved by introducing the proper b-carbon processing functions (p-ketoreductase, dehydratase and enoylreductase) in 3 5 the required modules. Exogenous modules constitute the source of specificities for starter and extender units other than those employed by Sac. erythraea for erythromycin biosynthesis, making it thereby possible to employ, for example, malonylCoA or or (2S)ethylmalonylCoA, etc.

i 1 Jt.

i ;i -ru- uc WO 93/13663 PCT/US92/00427 as extender units, and acetyl CoA, butyryl CoA, etc. as the starter unit. The result will be the formation of erythromycin analogs containing the desired functional groups and side chains with the desired stereochemistry. As an extension of the examples reported with eryA the construction of a Sac. erythraea strain carrying a heterologous module inserted into eryA requires: cloning of the genes from any other Actinomyces producing a polyketide with desired structural features; (ii) mapping of the modular organization of the cloned genes by low stringency hybridization and restriction analysis; (iii) locating the module 1 0 carrying the desired specificiies by partial sequencing; (iv) precise excision of the desired genetic element and cloning into a vector suitable for gene conversion; construction and transformation of a Sac. erythraea strain suitable for gene conversion and screening for the novel compound. Any module, or portion thereof, can thus be precisely excised from the genome of a polyketide-producing microorganism and introduced into suitable Sac. erythraea strains to create a novel polyketide of predicted structure.

Thus, replacement of the acyltransferase segments of modules 1, 2, 3, 4, 6 in eryA with the acyltransferase segment specific for malonyl CoA, such as can be found in the polyketide synthase genes for the synthesis of pikromycin in Streptomyces venezuelae, to result in the synthesis of 12norerythromycin A, 10-norerythromycin A, 8-norerythromycin A, 6norerythromycin A, 4-norerythromycin A and 2-norerythromycin A, respectively, that are included within the scope of the present invention.

In addition, replacement of the acyltransferase segments of modules 1, 2, 3, 4, 5,or 6 in eryA with an acyltransferase specific for (2R)-ethylmalonyl CoA, such as can be found in the polyketide synthase genes for the synthesis of spiramycin in Streptomvces ambofasciens will result in the formation of 12-homoerythromycin A, 10-homoerythromycin A, 8epihomoerythromycin A, 6-epihomoerythromycin A, 4epihomoerythromycin A and 2-homoerythromycin A, respectively, all of which are included within the scope of the present invention. Similarly, introduction of acyltransferase segments carrying desired specificities for the starter or extender unit into eryA DNA that results in the synthesis of novel compounds are included within the scope of the present invention.

The erythromycin analogs produced by the method of this invention are structurally similar to known antibacterial and prokinetic agents.

I It will also occur to those skilled in the art that genetic manipulations described herein need not be limited to Sac, erythraea.

i: WO 93/13663 PC/US92/00427 36 Suitable hosts are any other polyketide-produdng Actinomvce here DNA can be precisely inserted into the chromosome-Hence, the choice of a convenient host is based solely on the relatedness of the novel polyketide to a natural counterpart so as to minimize the number of module rearrangements required for its biosynthesis. Therefore, Type I, Type II and Type III alterations can be constructed in other Actinomyces employing either endogenous or exogenous modules to produce novel polyketides employing strategies analogous to those described herein for Sac. erythraea. Thus all Type I, Type II or Type I mutations or various 1 0 combinations thereof constructed in other actinomycetes according to the principles described herein, and the respective polyketides produced from such strains, are included within the scope of the present invention.

Examples of polyketides that can be altered by creating Type I, Type II or Type IM changes in the producing microorganisms include, but are not 1 5 limited to macrolide antibiotics such as erythromycin, tylosin, spiramycin, etc.; ansamacrolides such as rifamycins, maytansines, etc.; polyketide antibiotics such as tetracycline; polyethers such as monesin, salinomycin, etc.; polyenes such as candicidin, amphothericins; immunosuppressants such as FK506, ascomycin, rapamycin, etc. and other complex polyketides 2 0 such as avermectin.

Whereas the novel derivatives or modifications of erythromycin described herein have been specified as the A derivatives, such as 7hydroxyerythromycin A, 11-oxo-11-deoxyerythromycin A, 14[1(1hydroxypropyl)]erythromycin A, etc., those skilled in the art understand 2 5 that the wild type strain of Sac. erythraea produces a family of erythromycin compounds, including erythromycin A, erythromycin B, erythromycin C and erythromycin D. Thus, modified strains of Sac.

erythraea, such as strain AKR2, for example, would be expected to produce the corresponding members of the 11-oxo-11-deoxyerythromycin family, 3 0 including 11-oxo-11-deoxyerythromycin A, 11-oxo-11-deoxyerythromycin B, 11-oxo-11-deoxyerythromycin C, and 11-oxo-11-deoxyerythromycn D.

Similarly, strain AM412 would be expected to produce not only 14(1propyl)erythromycin A but also the other members of the 14(1propyl)erythromycin family including 14(1-propyl)erythromycin B, 14(1- 3 5 propyl)erythromycin C and 14(1-propyl)erythromycin D. Similarly, all other modified strains of Sac. erythraea described herein that produce novel erythromycin derivatives would be expected to produce the A, B, C, and D forms of said derivatives. Therefore, all members of the farily of WO 93/13663 PCT/US92/00427 37 each of the novel polyketides described herein are included within the scope of the present invention.

Variations and modifications of the methods for obtaining the desired plasmids, hosts for cloning and choices of vectors and segments of eryA DNA to clone and modify, other than those described herein that result in substantially the same strains and same products as those described herein will occur to those skilled in the art. For example, although we have described the use of the plasmids pWH3 and pWHM4 as E. coli-Sac. erythraea shuttle vectors, other vectors can be employed 1 0 wherein all or part of pWHM3 or pWHM4 is replaced by other DNA segments that function in a similar manner, such as replacing the pUC19 component of pWHM3 and pWHM4 with pBR322, available from BRL, employing different segments of the pIJ101 or pJV1 replicons in pWHM3 and pWHM4, respectively, or employing selectable markers other than 1 5 thiostrepton- and ampicillin-resistance. These are just few of a long list of possible examples all of which are included within the scope of the present invention. Similarly, the segments of the eryA locus subcloned into pWHM3 for generating strains AKS1, AKS2, etc. specified herein can readily be substituted for other segments of different length encoding the same functions, either produced by PCR-amplification of genomic DNA or of an isolated clone, or by isolating suitable restriction fragments from Sac.

erythraea. In the same way, it is possible to create eryA strains carrying mutations functionally equivalent to those described herein by deleting different portions of the corresponding genes, by creating insertions into them, or by site-directed mutagenesis of specific nucleotide residues.

Moreover, Sac. erythraea strains with mutant alleles other than the Pketoacyl ACP synthase portions of eryA can be employed as hosts for gene conversion; Type III mutants can be constructed by double reciprocal crossover as exemplified for Type I and Type II mutants rather than by the gene conversion method described herein. Additional modifications include changes in the restriction sites used for cloning or in the general methodologies described above. All such changes are included in the scope of the invention. It will also occur to those skilled in the art that different methods are available to ferment Sac. erythraea, to extract the 3 5 novel polyketides specified herein, and to synthesize substrate analogs, and that all such methods are also included within the scope of the present invention.

WO 93/13663 PCT/US92/00427 38 It will be apparent that many modifications and variations of the invention as set forth herein are possible without departing from the spirit and scope thereof, and that, accordingly, such limitations are imposed only as indicated by the appended claims.

I

i F i

Claims (30)

1. A method for directing the biosynthesis of specific polyketide analogs by genetic manipulation of a polyketide-producing microorganism, wherein said biosynthesis proceeds enzymatically by repeated condensation of carbonyl-containing extender units to an acyl starter unit or to a growing polyketide, each condensation adding two additional carbons to a backbone polyketide chain to synthesize a polyketide of defined length having a P-carbonyl group, said method comprising the steps of: isolating a polyketide biosynthetic gene-containing DNA sequence from a polyketide-producing microorganism of interest; identifying within said gene-containing DNA sequence the DNA fragment or fragments encoding for an enzymatic activity that is to be Otered to produce said specific polyketide analog; introducing one or more specified changes into said gene containing DNA sequence, thereby resulting in an altered DNA sequence which, when translated, results in altered enzymatic activity to produce said specific polyketide analog; introducing said altered DNA sequence into a polyketide producing microorganism to replace the original sequence; growing a culture of the altered microorganism under conditions suitable for the formation of the specific polyketide analog; and 20 isolating said specific polyketide analog from the culture. l; t

2. The method of claim 1 wherein said polyketide biosynthetic gene containing DNA sequence which is altered comprises genes which encode one or more enzymatic activities of a polyketide synthase.

3. The method of claim 2, wherein said enzymatic activities of a polyketide synthase are selected from the group consisting of p-ketoreductase, dehydratase, acyl carrier protein, enoylreductase, p-ketoacyl ACP synthase, and acyltransferase. ;t

4. The method of claim 1 wherein said specified change in the DNA sequence results in altered enzymatic activity involved in the processing of the p-carbonyl of said S polyketide.

5. The method of claim 4, wherein said specified change in the DNA sequence results in the inactivation of at least one enzyme activity selected from dehydratase, and enoylreductase.

6. The method of claim 4 wherein said specified change in the DNA sequence results in the addition of at least one enzyme activity selected from p-ketoreductase, dehydratase, and enoylreductase.

7. The method of claim 1 wherein said specified change in the DNA sequence results in altered enzymatic activity involved in the condensation of extender units to the acyl starter unit or to the growing polyketide. INA\LIBFFjO00261 SAK 0 i

8. The method of claim 7 wherein said specified change in the DNA sequence results in altered enzymatic activity selected from the activities of 0-ketoacyl ACP synthase, acyl carrier protein and acyltransferase.

9. The method of claim 8 wherein said specified change in the DNA sequence comprises the replacement of an existing DNA segment encoding an acyltransferase having substrate specificity for a first carbonyl-containing extender unit with a DNA segment encoding an acyltransferase having substrate specificity for a second, distinct carbonyl-containing extender unit.

The method of claim 7 wherein said specified change in the DNA sequence results in a polyketide analog having a backbone chain length shorter than a polyketide synthesized in the absence of said specified change, said polyketide analog being shorter by increments of two-carbons.

11. The method of claim 10 wherein said specified change in the DNA sequence comprises the deletion of DNA sequences encoding one or more enzymatic activities consisting of acyltransferase, acyl carrier protein and P-ketoacyl ACP synthase.

12. The method of claim 7 wherein said specified change in the DNA sequence results in a polyketide analog having a backbone chain length longer than a polyketide synthesized in the absence of said specified change, said polyketide analog being longer by increments of two-carbons.

13. The method of claim 12 wherein said specified change in the DNA sequence Scomprises the addition of DNA sequences encoding one or more enzymatic activities consisting of acyltransferase, acyl carrier protein and P-ketoacyl ACP synthase.

14. The method of claim 1 wherein said polyketide analog is synthesized by iterative condensation steps; wherein the enzymatic activities for each iteration are encoded by a distinct module encoding P-ketoacyl ACP synthase, acyl carrier protein and acyltransferase activities, the number of such modules determining the backbone length of the polyketide analog. St

15. The method of claim 14 wherein the specified change in DNA results in the addition or deletion within at least one such module of DNA encoding a p-carbonyl processing enzymatic activity selected from the activities of P-ketoreductase, dehydratase and enoylreductase. '"tr

16. The method of claim 14 wherein the specified change in DNA results in the S" addition or inactivation of essentially an entire module.

17. The method of claim 1 wherein said DNA sequence is isolated from a a3 polyketide-producing microorganism from the Actinomycetales family.

18. The method of claim 17 wherein said DNA sequence is isolated from a polyketide-producing microorganism in a genus selected from the group consisting of Actinomyces, Dactylosporangium, Micromonospora, Nocardia, Saccharapolyspora, Streptoverticillium, and Streptomyces. |(N:\LIOFF1OO261;SAK t Q< kb SstI(95)-SstI(101) fragment from plasmid pALeryAM4.2. With the first probe, the SphI band at 0.8 kb in strain AKS1 is seen to be replaced by a ]i i Ii Bs. u v~ II *t* I *1 c 5 -5 ''4 rtCI I N; (t*C C

19. The method of claim 18 wherein said genus is selected from the group consisting of Saccharapolyspora and Streptomyces.

The method of claim 19 wherein said polyketide-producing microorganism is a strain of Saccharapolyspora erythraea.

21. The method of claim 19 wherein said polyketide-producing microorganism is a strain of Streptomyces hygroscopicus.

22. The method of claim 1 wherein said polyketide is selected from the group consisting of macrolides, tetracyclines, polyethers, polyenes, ansaymcins and derivatives or analogs thereof.

23. The method of claim 22 wherein said polyketide is a macrolide.

24. The method of claim 23 wherein said macrolide is a rapamycin analog.

The method of claim 23 wherein said macrolide is an erythromycin.

26. The method of claim 25 wherein said erythromycin analog is selected from the group consisting of 11-oxo-1l-deoxyerythromycin A, 7-hydroxyerythromycin A, 6- deoxy-7-hydroxyerythromycin A, 7-oxoerythromycin A, 3-oxo-3-deoxy-5- desosaminylerythronolide A, A-6,7-anhydroerythromycin A, ((14S,15S)14(1- hydroxyethyl)erythromycin A, 11-epifluoro-15-norerythromycin A, 14(1- propyl)erythromycin A, and 14[1(1-hydroxypropyl)]erythromycin A.

27. The method of claim 1 wherein said gene-containing DNA sequence, designated eryA, encodes the enzymatic activities associated iwith the formation of 6- deoxyerythronolide B.

28. The method of claim 27 wherein said DNA sequence comprises the DNA sequence of Figure 2.

29. A compound selected from the group consisting of 7-hydroxyerythromycin A; 25 6-deoxy-7-hydroxyerythromycin A; 7-oxoerythromycin A, 3-oxo-3-deoxy-5-desosaminyl- erythronolide A; A-6,7-anhydroerythromycin A; ((14S,15S)14(1- hydroxyethyl)erythromycin A; 11-epifluoro-15-norerythromycin A; 14(1- propyl)erythromycin A; and 14[l(1-hydroxypropyl)]erythromycin A.

30. A method for directing the biosynthesis of specific polyketide analogs by so genetic manipulation of a polyketide-producing microorganism, wherein said biosynthesis proceeds enzymatically by repeated condensation of carbonyl-containing extender units to at acyl starter unit or to a growing polyketide, each condensation adding two additional carbons to a backbone polyketide chain to synthesize a polyketide of defined length having a P-carbonyl group, which method is substantially as hereinbefore described with reference to any one of the Examples. Dated 19 September, 1995 Abbott Laboratories Patent Attorneys for the Applicant/Nominated Person 5 SPRUSON FERGUSON Af v A'p (N:\LIBFF|0021 :SAK